Navigation Links
Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010
Date:12/16/2009

pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive NHL as determined by the FDA (including ODAC), CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.



    Media Contact:                        Investors Contact:
    Dan Eramian                           Ed Bell
    T: 206.272.4343                       T: 206.272.4345
    C: 206.854.1200                       Lindsey Jesch Logan
    F: 206.272.4434                       T: 206.272.4347
    E: deramian@ctiseattle.com            F: 206.272.4434
    www.celltherapeutics.com/press_room   E: invest@ctiseattle.com
                                          www.celltherapeutics.com/investors


SOURCE Cell Therapeutics, Inc.'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Quest Diagnostics (NYSE: DGX ), the world,s ... its Board of Directors has elected Jeffrey M. Leiden, ... 2014. Including Dr. Leiden, the Board has 11 members. ... CEO of Vertex Pharmaceuticals.   Dr. Leiden has more ... the pharmaceutical and biotechnology industries as well as clinical ...
(Date:10/22/2014)... , Oct 22, 2014 Antigen Discovery ... Irvine, California , announced the receipt of a ... Innovation Research award (SBIR) from the National Institute of Dental and ... the development of a Pan-HIV Protein Microarray Chip, which ... and HIV-2 subtypes and aid in the development of ...
(Date:10/22/2014)... , Oct. 22, 2014   Reproductive Medicine ... leader in the field of infertility, presents new ... embryonic screening. The research abstract, released during the ... Medicine (ASRM) meeting in Honolulu, Hawaii ... single gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
Breaking Medicine Technology:Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... EAST HANOVER, N.J., Aug. 27 The US Food ... tablets, a single-pill for the treatment of high blood ... (aliskiren), with the widely used calcium channel blocker amlodipine. ... are likely to need multiple drugs to achieve their ...
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results ... data.results) { first_result = data.results[r]; break; } for (var key in first_result) { //s += key ...
Cached Medicine Technology:Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 2Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 3Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 4Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 5Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 6Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 7STALLERGENES: Excellent 1st Half-Year 2010 Performance 2STALLERGENES: Excellent 1st Half-Year 2010 Performance 3STALLERGENES: Excellent 1st Half-Year 2010 Performance 4STALLERGENES: Excellent 1st Half-Year 2010 Performance 5STALLERGENES: Excellent 1st Half-Year 2010 Performance 6STALLERGENES: Excellent 1st Half-Year 2010 Performance 7
(Date:10/25/2014)... Barbara, CA (PRWEB) October 25, 2014 ... charity's annual President’s Circle Reception on Monday at the ... FSA’s accomplishments and hear from guest speaker Dr. Winifred ... digital worlds. , Dr. Lender, a Santa Barbara psychologist, ... the challenges and benefits of living in the digital ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 TASC ... medical and other benefits account management services, announces ... help employers save on taxes, reduce administrative workload, ... provide tax savings and the efficient handling of ... the Suite that best meets their goals and ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 ... Molecular Diagnostics Industry, 2009-2019 is a professional ... Chinese Molecular Diagnostics industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Molecular Diagnostics listing their ...
(Date:10/25/2014)... Homeowners that are wondering how they can ... no more. Clean Crawls gives 5 signs of ... when it comes to insulation in their recently released ... by Clean Crawls, can cause problems throughout your entire ... has deteriorated, become damp, or been infested with pests ...
(Date:10/25/2014)... October 25, 2014 Mesothelioma researchers are ... to receive pemetrexed (Alimta), after his combination drug therapy ... full story , just posted on the Surviving Mesothelioma ... Tokushukai Medical Center in Japan suggests that “maintenance therapy” ... patients who cannot tolerate higher doses of cisplatin. ...
Breaking Medicine News(10 mins):Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2
... Balehonnur-based Central Coffee Research Institute (CCRI) has said that it ... in December 2007 . ,After 21 years of ... December 15. The yet-to-be named hybrid, hi-yielding arabica variety is ... resistant to the widely prevalent white stem borer. ...
... again when she was pictured with baby bump . ... Travolta starrer Hairspray dressed in a figure-hugging black dress that ... ,Holmes sparked off rumours that she and hubby ... spotted with bump while visiting new best friends David and ...
... the entire Test series against India with a hernia injury.Harmison ... to six weeks, reports BBC . ,England coach ... back and now it's all about getting the operation done ... Chris Tremlett are vying for the third seamer's spot for ...
... government was not averse to inviting the World Health Organisation ... fever in the state that has claimed 173 lives this ... arrived in the state since the outbreak of the fever, ... the fever as chikunguniya and nothing else, we have no ...
... dysfunction can overcome their problem by taking part in ... ,The study also suggests that supplementing sildenafil, ... other names, to group therapy can make the treatment ... sexual function relies on the coordination of psychological, endocrine, ...
... The Punjab University has reserved seats for students suffering from ... ,The University has reserved one seat for each of ... AIDS or suffering from cancer. ,However, the university ... sufficient for the time being, since it do not expects ...
Cached Medicine News:Health News:Harmison Ruled Out Off Test Series Due to Hernia 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: